Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.

Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.

Veure altres versions (1)

Malaria transmission is in decline in some parts of Africa, partly due to the scaling up of control measures. If the goal of elimination is to be achieved, additional control measures including an effective and durable vaccine will be required. Studies utilising the prime-boost approach to deliver v...

Descripció completa

Dades bibliogràfiques
Autors principals:	Mensah, V, Gueye, A, Ndiaye, M, Edwards, N, Wright, D, Anagnostou, N, Syll, M, Ndaw, A, Abiola, A, Bliss, C, Gomis, J, Petersen, I, Ogwang, C, Dieye, T, Viebig, N, Lawrie, A, Roberts, R, Nicosia, A, Faye, B, Gaye, O, Leroy, O, Imoukhuede, E, Ewer, K, Bejon, P, Hill, A, Cisse, B, MVVC Group
Format:	Journal article
Idioma:	English
Publicat:	Public Library of Science 2016

Ítems similars

Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.
per: Victorine A Mensah, et al.
Publicat: (2016-01-01)

Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African children and infants
per: Bliss, C, et al.
Publicat: (2016)

First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children
per: Tiono, AB, et al.
Publicat: (2018)

Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.
per: Ogwang, C, et al.
Publicat: (2013)

A Phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS
per: De Barra, E, et al.
Publicat: (2014)

Safety and immunogenicity of the heterologous prime-boost ebolavirus vaccine regimen CHAD3-EBO Z and MVA-BN (R) FILO in healthy UK adults
per: Rampling, T, et al.
Publicat: (2015)

Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals.
per: Hodgson, S, et al.
Publicat: (2014)

Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations.
per: Kimani, D, et al.
Publicat: (2014)

First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children.
per: Alfred B Tiono, et al.
Publicat: (2018-01-01)

Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.
per: Caroline Ogwang, et al.
Publicat: (2013-01-01)

Safety and high level efficacy of the combination malaria vaccine regimen of RTS,S/AS01B with ChAd-MVA vectored vaccines expressing ME-TRAP
per: Rampling, T, et al.
Publicat: (2016)

Evaluation of the efficacy of chad63-mva vectored vaccines expressing circumsporozoite protein and me-trap against controlled human malaria infection in malaria-naive individuals
per: Hodgson, SH, et al.
Publicat: (2014)

A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS.
per: Eoghan de Barra, et al.
Publicat: (2014-01-01)

Phase Ia clinical evaluation of the plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors
per: Sheehy, S, et al.
Publicat: (2011)

Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors.
per: Sheehy, S, et al.
Publicat: (2011)

Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.
per: Sheehy, S, et al.
Publicat: (2012)

Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection.
per: Elias, S, et al.
Publicat: (2014)

ChAd63-MVA-vectored blood-stage Malaria vaccines targeting MSP1 and AMA1: Assessment of efficacy against mosquito bite challenge in humans
per: Sheehy, S, et al.
Publicat: (2012)

ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans.
per: Sheehy, S, et al.
Publicat: (2012)

Safety and Efficacy of Novel Malaria Vaccine Regimens of RTS,S/AS01B alone, or with Concomitant ChAd63-MVA Vectored Vaccines Expressing ME-TRAP
per: Rampling, T, et al.
Publicat: (2018)

Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure
per: Biswas, S, et al.
Publicat: (2014)

Impact of exposure to malaria and nutritional status on responses to the experimental malaria vaccine ChAd63 MVA ME-TRAP in 5-17 month-old children in Burkina Faso
per: Richard Morter, et al.
Publicat: (2022-12-01)

Safety and immunogenicity of the novel plasmodium falciparum blood-stage vaccine chad63-mva rh5 in a phase ia clinical trial
per: Payne, R, et al.
Publicat: (2017)

Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure.
per: Sumi Biswas, et al.
Publicat: (2014-01-01)

Durability of immune responses induced by three leading candidate ebola vaccine regimes; rVSV ZEBOV, ChAd3 EBO Z-MVA BN-Filo and AdHu26.ZEBOV-MVA BN Filo
per: Ewer, K, et al.
Publicat: (2018)

A monovalent chimpanzee adenovirus ebola vaccine boosted with MVA
per: Ewer (nee Russell), K, et al.
Publicat: (2016)

Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial
per: Hans de Graaf, et al.
Publicat: (2021-07-01)

Safety and immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I first-in-human trial
per: de Graaf, H, et al.
Publicat: (2021)

Impact of exposure to malaria and nutritional status on responses to the experimental malaria vaccine ChAd63 MVA ME-TRAP in 5-17 month-old children in Burkina Faso
per: Morter, R, et al.
Publicat: (2022)

Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation
per: Ewer, K, et al.
Publicat: (2013)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naive subjects gives comparable immunogenicity to one dose in ART+ subjects
per: Dieye, T, et al.
Publicat: (2013)

Viral vector malaria vaccines induce high-level T cell and antibody responses in West African children and infants
per: Bliss, C, et al.
Publicat: (2016)

Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.
per: O'Hara, G, et al.
Publicat: (2012)

HETEROLOGOUS PRIME-BOOST VACCINATION WITH ADCH63 AND MVA EXPRESSING MSP1 CAN INDUCE PROTECTIVE EFFICACY AGAINST SPOROZOITE CHALLENGE IN VOLUNTEERS
per: Sheehy, S, et al.
Publicat: (2010)

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity
per: Rowland, R, et al.
Publicat: (2012)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects.
per: Tandakha N Dieye, et al.
Publicat: (2013-01-01)

Correction: Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects.
per: Tandakha N. Dieye, et al.
Publicat: (2013-01-01)

Safety and immunogenicity of malaria vectored vaccines given with routine EPI vaccines in Gambian infants and neonates: a randomized controlled trial
per: Mensah, V, et al.
Publicat: (2017)

Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial
per: Victorine A. Mensah, et al.
Publicat: (2017-11-01)

O'nyong-nyong Virus, Chad
per: Maël Bessaud, et al.
Publicat: (2006-08-01)